Sixty-three percent alive at one year versus thirty percent on chemotherapy
In the long struggle against one of lung cancer's most unforgiving forms, a new compound called gotistobart has emerged from a Chicago conference with data suggesting it may do what few treatments have managed: meaningfully extend life for patients who have already exhausted their options. Developed by BioNTech and OncoC4, the drug works not by poisoning cancer cells but by selectively reawakening the immune system within the tumor itself. For a disease where median survival rarely exceeds eleven months after standard therapies fail, a fifty-four percent reduction in death risk is the kind of signal that quietly shifts the horizon of possibility.
- Squamous non-small cell lung cancer kills with speed and few second chances — once immunotherapy fails, patients face a median survival of roughly eleven months with almost nothing left to offer them.
- Gotistobart's Phase 3 trial data, presented at a major oncology conference in Chicago, showed patients on the drug had not yet reached median survival at nearly fifteen months of follow-up, while those on standard chemotherapy reached it at ten months.
- The drug's pH-sensitive mechanism — selectively depleting immune-suppressing cells inside the acidic tumor environment while sparing healthy tissue — represents a fundamentally different approach from anything currently approved for this population.
- The safety profile held: fewer severe adverse events than chemotherapy, no unexpected toxicity, and a manageable treatment burden for patients who have already endured much.
- A global pivotal trial enrolling roughly five hundred patients across more than a dozen countries is now underway, with FDA Fast Track and China Breakthrough Therapy designations accelerating the path toward potential approval.
At a major oncology conference in Chicago, researchers unveiled early results from a clinical trial that could change how doctors approach one of lung cancer's most aggressive subtypes. The drug, gotistobart — developed jointly by BioNTech and OncoC4 — cut the risk of death by fifty-four percent compared to standard chemotherapy in patients whose squamous non-small cell lung cancer had already stopped responding to immunotherapy.
This is a population with almost nowhere left to turn. Squamous non-small cell lung cancer accounts for roughly one in four lung cancer cases, and once standard immunotherapy fails, median survival in the United States sits around eleven months. The five-year survival rate is fifteen percent. Gotistobart was tested in this exact group: eighty-seven patients who had already failed both immunotherapy and chemotherapy. Those receiving the drug had not yet reached median survival at nearly fifteen months of follow-up, while those on docetaxel chemotherapy reached it at ten months. At the twelve-month mark, sixty-three percent of gotistobart patients were still alive, compared to thirty percent on chemotherapy.
What distinguishes the drug is its mechanism. Gotistobart is a pH-sensitive antibody targeting CTLA-4, a protein on regulatory T cells that normally suppress immune activity. Inside the acidic environment of a tumor, the drug binds, enters the cell, and releases — allowing the protein to recycle while selectively depleting immune suppression where it matters most. The effect is a more targeted immune reawakening, without the broad toxicity of chemotherapy. Adverse events were slightly lower than in the chemotherapy arm, and no unexpected safety signals emerged.
The pivotal stage of the trial is now enrolling approximately five hundred patients across more than one hundred sixty sites in a dozen countries. The FDA granted Fast Track Designation in 2022; China's regulators followed with Breakthrough Therapy Designation in 2025. BioNTech is also exploring the drug alongside its mRNA cancer vaccine platform. For patients who have run out of options, gotistobart represents something genuinely new — and the field is watching closely to see whether these early signals hold.
In Chicago this week, researchers presented results from a clinical trial that may reshape how doctors treat one of lung cancer's most aggressive forms. The drug is called gotistobart, developed jointly by BioNTech and OncoC4, and the early data suggests it cuts the risk of death in half compared to the chemotherapy patients typically receive when their tumors stop responding to immunotherapy.
Squamous non-small cell lung cancer is a brutal disease. About one in four lung cancers are this subtype, and patients who progress after immunotherapy face grim odds. The median survival for these patients sits around eleven months in the United States. Once standard immunotherapy fails, doctors have limited options: more chemotherapy or palliative care. The five-year survival rate hovers near fifteen percent. Into this landscape comes gotistobart, a drug designed to work differently than anything currently available.
The trial, called PRESERVE-003, enrolled eighty-seven patients with advanced squamous lung cancer who had already failed immunotherapy and chemotherapy. Forty-five received gotistobart as a single agent. Forty-two received docetaxel, the standard chemotherapy option. At the data cutoff in August, the results were striking. Patients on gotistobart had not yet reached a median survival time at fourteen and a half months of follow-up. Those on docetaxel reached median survival in ten months. The hazard ratio showed a fifty-four percent reduction in death risk for the gotistobart group. At twelve months, sixty-three percent of gotistobart patients were still alive, compared to thirty percent of those on chemotherapy.
What makes gotistobart distinctive is its mechanism. It is a pH-sensitive antibody that targets CTLA-4, a protein on immune cells called regulatory T cells. These cells normally suppress the immune system to prevent autoimmunity. In tumors, they suppress anti-cancer immunity. Gotistobart binds to CTLA-4, gets pulled inside the cell, and then unbinds in the acidic environment inside—allowing the protein to recycle back to the surface. This selective depletion happens preferentially in the acidic tumor microenvironment, theoretically sparing immune regulation in healthy tissues. The result is enhanced anti-tumor immunity without the broad immune suppression that comes with traditional chemotherapy.
The safety profile was manageable. Forty-two percent of gotistobart patients experienced grade three or higher treatment-related adverse events, compared to forty-nine percent on docetaxel. Neither arm showed unexpected toxicity. Byoung Chul Cho, the lead investigator and a professor at Yonsei Cancer Center in Seoul, called the survival data encouraging and said the team remains excited to continue the ongoing pivotal stage of the trial.
That pivotal stage is now enrolling approximately five hundred patients across more than one hundred sixty sites globally, including Australia, Belgium, Canada, China, Germany, Italy, the Netherlands, Spain, South Korea, Turkey, the United Kingdom, and the United States. The primary endpoint is overall survival. The FDA granted gotistobart Fast Track Designation in 2022 for patients with metastatic lung cancer whose disease progressed on prior anti-PD-L1 therapy, and China's regulatory authority granted Breakthrough Therapy Designation in 2025. BioNTech is also exploring gotistobart in combination with its own mRNA cancer vaccine candidate, and OncoC4 is running separate trials in ovarian cancer and prostate cancer.
For patients with squamous non-small cell lung cancer, this represents something genuinely new: a chemotherapy-free option with a different mechanism of action, tested in people for whom standard treatments have failed. The pivotal trial will determine whether these early signals translate into a meaningful advance. Until then, the field watches.
Citas Notables
With a median survival of less than a year, advanced squamous NSCLC remains an aggressive and difficult-to-treat lung cancer. Patients who progress on anti-PD-L1 inhibitor treatment face a poor prognosis, leaving them only with the option of chemotherapy or palliative care.— Byoung Chul Cho, M.D., Ph.D., Lead Investigator and Professor at Yonsei Cancer Center, Seoul
Gotistobart represents a step forward in our goal of offering a chemotherapy-free treatment option for patients with advanced squamous NSCLC, a population with limited therapeutic choices and a lack of actionable biomarkers to guide treatment.— Pan Zheng, M.D., Ph.D., Chief Medical Officer and Co-Founder at OncoC4
La Conversación del Hearth Otra perspectiva de la historia
Why does this particular lung cancer subtype matter so much? Isn't lung cancer lung cancer?
Squamous cell carcinoma behaves differently from the adenocarcinomas that dominate the statistics. It's more aggressive, more resistant to current immunotherapies, and it leaves patients with almost no options once they've exhausted the standard approach. About one in four lung cancers are squamous, but they account for a disproportionate share of the suffering.
The fifty-four percent reduction in death risk—that's the headline. But what does that actually mean for a patient sitting in an oncologist's office?
It means if you're on chemotherapy, you have a ten-month median survival. On gotistobart, you haven't hit that median yet at fifteen months. At one year, you're twice as likely to be alive. But this is early data from forty-five people. The pivotal trial with five hundred patients will tell us whether that holds up and whether it's real or statistical noise.
The mechanism sounds elegant—this pH-sensitive unbinding. Is that actually important, or is it marketing?
It matters because it's designed to spare healthy tissue. Traditional chemotherapy kills dividing cells everywhere. This drug theoretically works preferentially in the acidic tumor environment. Whether that translates to fewer side effects in practice—that's what the larger trial will show. The early safety data look similar to chemotherapy, which is honest.
What happens to these patients if gotistobart doesn't get approved?
They stay on chemotherapy or move to palliative care. The median survival for squamous NSCLC after immunotherapy failure is eleven months. That hasn't changed much in years. This drug, if it works, would be the first real alternative.
Why is BioNTech, a company famous for mRNA vaccines, developing this antibody?
They're building a diversified oncology portfolio. They have the capital, the infrastructure, and the partnerships. OncoC4 brought the science on this particular mechanism, and BioNTech brought the resources and global reach to run a massive trial. It's how modern drug development works—collaboration across companies.
What's the next milestone?
The pivotal stage enrollment and the data that comes from it. Five hundred patients is a real test. If the survival benefit holds and safety remains manageable, this becomes a regulatory submission. If it doesn't, it's back to the drawing board. We'll probably see interim data in the next year or two.